Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $769.00 Price Target at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by analysts at Truist Financial from $778.00 to $769.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 18.34% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Barclays reduced their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Finally, Canaccord Genuity Group decreased their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $790.92.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $649.81 on Tuesday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a twelve month low of $532.60 and a twelve month high of $821.11. The company has a fifty day moving average of $652.48 and a 200-day moving average of $725.31. The firm has a market capitalization of $68.70 billion, a P/E ratio of 15.83, a P/E/G ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm earned $8.22 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.44 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nordea Investment Management AB grew its position in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $2,702,000. Mackenzie Financial Corp grew its holdings in Regeneron Pharmaceuticals by 26.8% during the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock valued at $72,321,000 after buying an additional 27,205 shares in the last quarter. Asio Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $3,422,000. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in shares of Regeneron Pharmaceuticals by 116.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after buying an additional 140,966 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.